Search: id:"swepub:oai:DiVA.org:umu-151551" >
Single-cell heterog...
-
Buus, Terkild Brink
(author)
Single-cell heterogeneity in Sézary syndrome
- Article/chapterEnglish2018
Publisher, publication year, extent ...
-
2018-08-23
-
American Society of Hematology,2018
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:umu-151551
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-151551URI
-
https://doi.org/10.1182/bloodadvances.2018022608DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Sezary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with a median life expectancy of less than 4 years. Although initial treatment responses are often good, the vast majority of patients with SS fail to respond to ongoing therapy. We hypothesize that malignant T cells are highly heterogeneous and harbor subpopulations of SS cells that are both sensitive and resistant to treatment. Here, we investigate the presence of single-cell heterogeneity and resistance to histone deacetylase inhibitors (HDACi) within primary malignant T cells from patients with SS. Using single-cell RNA sequencing and flow cytometry, we find that malignant T cells from all investigated patients with SS display a high degree of single-cell heterogeneity at both the mRNA and protein levels. We show that this heterogeneity divides the malignant cells into distinct subpopulations that can be isolated by their expression of different surface antigens. Finally, we show that treatment with HDACi (suberanilohydroxamic acid and romidepsin) selectively eliminates some subpopulations while leaving other subpopulations largely unaffected. In conclusion, we show that patients with SS display a high degree of single-cell heterogeneity within the malignant T-cell population, and that distinct subpopulations of malignant T cells carry HDACi resistance. Our data point to the importance of understanding the heterogeneous nature of malignant SS cells in each individual patient to design combinational and new therapies to counter drug resistance and treatment failure.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Willerslev-Olsen, Andreas
(author)
-
Fredholm, Simon
(author)
-
Blumel, Edda
(author)
-
Nastasi, Claudia
(author)
-
Gluud, Maria
(author)
-
Hu, Tengpeng
(author)
-
Lindahl, Lise M.
(author)
-
Iversen, Lars
(author)
-
Fogh, Hanne
(author)
-
Gniadecki, Robert
(author)
-
Litvinov, Ivan V.
(author)
-
Persson, Jenny L.Umeå universitet,Institutionen för molekylärbiologi (Medicinska fakulteten),Clinical Research Center, Lund University, Malmö, Sweden(Swepub:umu)jepe0128
(author)
-
Bonefeld, Charlotte Menne
(author)
-
Geisler, Carsten
(author)
-
Christensen, Jan Praysgaard
(author)
-
Krejsgaard, Thorbjorn
(author)
-
Litman, Thomas
(author)
-
Woetmann, Anders
(author)
-
Odum, Niels
(author)
-
Umeå universitetInstitutionen för molekylärbiologi (Medicinska fakulteten)
(creator_code:org_t)
Related titles
-
In:Blood Advances: American Society of Hematology2:16, s. 2115-21262473-95292473-9537
Internet link
Find in a library
To the university's database
- By the author/editor
-
Buus, Terkild Br ...
-
Willerslev-Olsen ...
-
Fredholm, Simon
-
Blumel, Edda
-
Nastasi, Claudia
-
Gluud, Maria
-
show more...
-
Hu, Tengpeng
-
Lindahl, Lise M.
-
Iversen, Lars
-
Fogh, Hanne
-
Gniadecki, Rober ...
-
Litvinov, Ivan V ...
-
Persson, Jenny L ...
-
Bonefeld, Charlo ...
-
Geisler, Carsten
-
Christensen, Jan ...
-
Krejsgaard, Thor ...
-
Litman, Thomas
-
Woetmann, Anders
-
Odum, Niels
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood Advances
- By the university
-
Umeå University